Introduction
The role of RTKs in the etiology and/or progression of human malignancies is well established. Mechanisms leading to oncogenic activation of RTKs include overexpression and/or ampli®cation, creation of an autocrine stimulation loop, as well as structural alterations, such as point mutations, deletions and chromosomal rearrangements, that confer ligandindependent receptor activation. Although the mechanism leading to oncogenic activation of RTKs in human cancer may dier, in all cases the outcome is the same: a deregulation of the normally tightly regulated cellular signaling of the receptor (for reviews see Blume-Jensen and Hunter, 2001) .
Binding of ligand to the extracellular domain of a RTK promotes receptor dimerization/oligomerization and consequently, activation of the intracellular kinase domain and autophosphorylation of the receptor on tyrosine residues. The phosphotyrosine residues located outside the catalytic domain of the receptor may act as speci®c binding sites for a variety of signaling proteins. These contain Src homology 2 (SH2) or phosphotyrosine binding (PTB) domains, and recognize phosphorylated tyrosine residues in the context of their surrounding amino acids. RTKs therefore act as docking proteins to assemble multiprotein complexes, and the combination of proteins recruited to the RTK initiates a series of signals that culminate in distinct biological responses (review in Pawson, 1995) .
In the past few years, much eort has been aimed at elucidating the individual contribution of signaling proteins recruited to RTKs in biological events such as cell division, apoptosis, anchorage-independent cell growth, motility and invasiveness, which, if not strictly coordinated, contribute to a neoplastic phenotype. Various strategies including the overexpression of individual signaling proteins, such as the adaptor protein Shc Salcini et al., 1994) , or the expression of a constitutively activated form of an enzyme involved in signal transduction, such as PI3'K (Klippel et al., 1998) , have been used to elucidate the contribution of distinct signaling pathways. Moreover, the use of add-back mutant RTKs has allowed the study of the biological activity of distinct signaling pathways (Dankort et al., 1997 (Dankort et al., , 2001 ; Kazlauskas et al., 1991) . Although enhancing our understanding of the contribution of RTK activated signals to cellular transformation, these strategies have some limitations. The aforementioned add-back approach is restricted to the signaling molecules binding to the receptor investigated. The overexpression or use of constitutively activated signaling proteins is limited, in that the normal cellular regulatory mechanisms may be ineective. Therefore, we aimed to develop a¯exible model to investigate the individual contributions of dierent RTK-associated proteins to cell transformation and metastasis.
The Met tyrosine kinase, the receptor for hepatocyte growth factor/scatter factor, is overexpressed and ampli®ed in a number of human tumors and activating point mutations have been found in both sporadic and hereditary papillary renal carcinomas (Jeers et al., 1996) . The Met receptor was ®rst identi®ed as an oncoprotein, Tpr ± Met (Cooper et al., 1984) , a product of chromosomal rearrangement that fused a leucine zipper dimerization domain to the Met cytoplasmic domain, generating a constitutively activated kinase (Park et al., 1986; Rodrigues and Park, 1993) . This mechanism of oncogenic activation is now considered a paradigm for receptor oncoproteins activated following chromosomal translocation, including the Ret, TrkA, and PDGF receptors (Rodrigues and Park, 1994) .
Tpr-Met and Met receptor signaling, as well as biological activity, are dependent on two phosphotyrosine residues outside of the catalytic domain (Tyr-482 and 489 in Tpr ± Met, Tyr-1349 and 1356 in Met). Tyrosine 489 provides a direct binding site for the Grb2 and Shc adaptor proteins (Fixman et al., 1995 (Fixman et al., , 1996 Ponzetto et al., 1994) . In addition, Y482 and Y489 are required for the recruitment of the docking protein Gab1 which couples the Met receptor with multiple downstream signaling proteins including PI3'K, PLCg, the tyrosine phosphatase SHP2 and the adapter protein Crk (Bardelli et al., 1997; Maroun et al., 1999; Nguyen et al., 1997; Weidner et al., 1996) . Moreover, Grb2 acts to indirectly recruit the c-Cbl ubiquitin ligase, and contributes to the recruitment of Gab1 (Bardelli et al., 1997; Fixman et al., 1997; Lock et al., 2000) . Hence, the direct contribution of any of these signaling proteins in cell transformation is still unclear. Structure function studies had indicated that recruitment of Grb2 to the Tpr ± Met oncoprotein was required for ecient cell transformation (Fixman et al., 1996; Ponzetto et al., 1996) , and that the addition of a second Grb2 binding site enhanced cell transformation (Bardelli et al., 1999) . However, these studies had not directly addressed if Grb2 or Shc recruitment alone was sucient for cell transformation.
The observation that two tyrosine residues act as a multisubstrate binding site within the Met receptor, is in contrast to many other RTKs. For instance, the PDGF, EGF and NGF (TrkA) receptors have multiple tyrosine residues outside of their catalytic domains which are phosphorylated upon activation and many of these phosphotyrosine residues are binding sites for a single signaling protein (review in Pawson, 1995) . We took advantage of this unique feature of Tpr ± Met to engineer variants capable of directly recruiting only one signaling protein and consequently, to activate in isolation its downstream signal transduction pathway. We have generated Tpr ± Met variants that speci®cally bind to the p85 subunit of PI3'K, PLCg, or the Grb2 or Shc adaptor proteins and have analysed their ability to induce focus formation, anchorage-independent cell growth, dispersal of epithelial cells, and experimental metastasis. These studies demonstrate that the recruitment of the Grb2 or the Shc adaptor proteins to RTK derived oncogenes is sucient for morphological cell transformation and experimental metastasis.
Results

Design and expression of substrate specific variants of the Tpr ± Met oncoprotein
To engineer Tpr ± Met variants capable of directly recruiting one signaling protein and consequently, to activate in isolation the downstream signal transduction pathways, we took advantage of the fact that the substrate recruitment and the transforming activity of the Tpr-Met oncoprotein depend on two tyrosine residues (Y482 and Y489) in its carboxy-terminus (Fixman et al., 1996; Ponzetto et al., 1994) . Using Tpr ± Met mutant where tyrosine 482 was substituted with a nonphosphorylatable phenylalanine residue (Y482F), we introduced restriction sites (HpaI/NarI) allowing the substitution of tyrosine 489, and surrounding amino acids (486 to 494), with amino acids derived from other RTKs that correspond to binding motifs for a single signaling protein (Figure 1a) . To evaluate the role of receptor-associated signaling proteins to cellular transformation, we generated Tpr ± Met variants predicted to bind individually to the p85 subunit of PI3'K, PLCg, or to the Grb2 or Shc adaptor proteins (see Table 1 ), in addition to negative controls for Grb2 and Shc where the inserted tyrosine residue was substituted with a nonphosphorylatable phenylalanine residue (Y/F).
The expression of each variant was examined following transient transfection in COS-1 cells. The wild-type, mutant and variant Tpr ± Met proteins were immunoprecipitated with an antibody raised against the carboxy-terminus of the Met receptor (Ab 144, Rodrigues et al., 1991) and analysed by Western immunoblotting using either Met or phosphotyrosine antibodies. Each variant was expressed as a protein with an apparent molecular weight of 65 kDa constitutively phosphorylated on tyrosine residues to a level comparable to the Tpr ± Met protein (Figure 1b) . Since the double Y482/489F mutant lacks the carboxyterminal tyrosine residues, this protein ran with an increased mobility (Fixman et al., 1996) . Furthermore, the ability of the Tpr ± Met kinase to phosphorylate itself and an exogenous substrate (myelin basic protein) was similar for all variants and was comparable to Tpr ± Met as con®rmed by in vitro kinase assays (data not shown).
Specific binding of PI3'K, PLCg, Grb2 and Shc to their respective variants
The Y482/489F Tpr ± Met mutant lacks the ability to recruit any known signaling proteins (Fixman et al., 1996 Ponzetto et al., 1994) . Since each variant corresponds to a Y482/489F mutant with the substitution of a speci®c binding site for amino acids 486 ± 494, the gained binding capacity and speci®city of each variant was compared to the Y482F/489F mutant following transient transfection into COS-1 cells. Variant Tpr ± Met proteins were immunoprecipitated using anti-Met sera and subsequently immunoblotted for each signaling protein of interest. Coimmunoprecipitation of the p85 subunit of PI3'K and PLCg was predominantly observed with the Y-p85 and Y-PLCg variants, respectively, but not with the Grb2 binding variant, nor with the Y482/489F mutant (Figure 2a,b) . Although low levels of p85 subunit and PI3'K activity were associated with the Y-Shc-1 and Y-Shc-1 (Y/F) variants, the level of the p85 subunit and PI3'K activity linked to the Y-p85 variant was greatly enhanced compared to Tpr ± Met (Figure 2a) . Similarly, the PLCg enzyme was tyrosine phosphorylated, an index of its activation (Kim et al., 1991) , only in cells expressing the PLCg binding variant, or Tpr ± Met or Y482F mutant (Figure 2b ). The enhanced binding of the p85 subunit and PLCg enzyme to their respective variants was not due to dierences in expression of each of the binding variants, since similar levels of protein were detected in all transfected cells (Figure 2a, b) .
The Grb2 binding variant coimmunoprecipitated Grb2 to a similar extent as Tpr ± Met or Y482F mutant (Figure 3a) , that both contain a consensus Grb2 binding site involving Y489 (YVNV). Moreover, Grb2 was recruited to a lesser extent with the Y-Shc-1 variant, but not with the Y-Shc-2, the Y-p85, or the YPLCg variants, although equivalent levels of these proteins were expressed (Figure 3a, c) . In an in vitro association assay, a GST-Grb2-SH2 domain fusion protein associates with the Y-Grb2 variant but not with the Shc binding variants, implying that the low level of coimmunoprecipitation of Grb2 with the YShc-1 variant is indirect (data not shown).
The Shc adaptor protein can interact with phosphotyrosine residues using either its SH2 or PTB domain (Pawson, 1995) . The Y-Shc-1 variant was designed based on the Shc PTB domain recognition motif of the TrkA receptor (Dikic et al., 1995) , whereas the Y-Shc-2 variant was derived from the Shc PTB/SH2 binding site of the EGFR (Table 1, Sakaguchi et al., 1998) . To determine whether these binding sites retained their binding speci®cities when substituted in Tpr ± Met, the (Figure 3c ). As expected, this interaction was mediated through the Grb2 SH2 domain as demonstrated from in vitro association assays using a GST-Grb2-SH2 fusion protein ( Figure  3c ).
Signals downstream of Shc or Grb2, but not PI3'K or PLCg binding variants are sufficient for focus formation
To test the contribution of each signaling protein in oncogenic transformation, focus forming assays were carried out following retroviral infection of Fisher Rat 3T3 ®broblast (Fr3T3) cells with each variant. The YShc-1 variant displayed the highest transformation eciency compared to any other variants (83% relative to Tpr ± Met, Figure 4a and Table 2 ). The Y-Grb2 and Y-Shc-2 variants displayed intermediate transforming ability (45 and 42%, respectively), whereas the Y-p85 and Y-PLCg variants induced with low eciencies foci of less dense cells (14 and 2%, respectively). Importantly, the transforming ability of the Grb2 or Shc binding variants was dependent upon phosphorylation of the tyrosine residue contained within the inserted amino acid sequence, as the Y-Grb2 (Y/F) or Y-Shc-1 (Y/F) variants failed to transform cells and behaved in a similar manner to the Y482/489F protein ( Figure 4a and Table 2 ). Similar results were obtained when focus (Bardelli et al., 1999; Weidner et al., 1995; Zhu et al., 1994) , the Tpr ± Met induced dispersal of epithelial colonies as evidenced from loss of cell ± cell contacts and the acquisition of a ®broblastoid cell morphology, whereas the Y482/489F mutant failed to promote epithelial cell dispersal (Figure 5a ). Variants binding to Grb2, Shc or PI3'K each promoted dispersal of epithelial colonies, whereas the PLCg, or negative controls for the Grb2 or Shc binding variants were unable to induce breakdown of cell-cell junctions and cells remained in contact within the colonies.
Cells expressing the Shc or Grb2, but not PI3'K or PLCg binding variants form experimental metastasis
The metastatic activity of the ®broblasts transformed by each variant was tested in an experimental metastasis assay. Nude mice injected into the tail vein with cells expressing the Grb2 or Shc binding variants showed extensive lung metastasis within 35 days, whereas cells expressing the PI3'K or PLCg binding variants failed to show signi®cant lung colonization and behaved in a similar manner to cells expressing the variant negative controls (Y-Grb2 Y/F or Y-Shc-1 Y/ F), or Y482/489F mutant ( Figure 5b and Table 2 ). As anticipated, cells expressing the Tpr ± Met or Y482F mutant showed ecient lung colonization (Bardelli et al., 1999; Jeers et al., 1998) . Hence, these data show that coupling with Grb2 or Shc is sucient for both transformation and metastatic spread of ®broblasts.
Phosphorylation of Gab1 and c-Cbl docking proteins does not correlate with the efficiency of cell transformation
Phosphorylation of the c-Cbl ubiquitin ligase and the Gab1 docking proteins has been correlated with the ability of Tpr ± Met, and of other receptors, to bind to Grb2, although Grb2-independent recruitment of Gab1 to Tpr ± Met has been demonstrated (Bardelli et al., 1997; Fixman et al., 1997; Fukazawa et al., 1996; Lock et al., 2000; Meisner and Czech, 1995; Nguyen et al., 1997; Weidner et al., 1996) . Moreover, the phosphorylation of c-Cbl and Gab1 was found to correlate with cellular transformation by Tpr ± Met (Bardelli et al., 1997; Fixman et al., 1997) . To better de®ne a role for Gab1 or c-Cbl in cell transformation, their phosphorylation levels were assayed in lysate of variant expressing cells. As demonstrated previously (Bardelli et al., 1997; Fixman et al., 1997) , both c-Cbl and Gab1 proteins were tyrosine phosphorylated in cells expressing Tpr ± Met, but not in cells expressing the Y482/ 489F mutant protein ( Figure 6 ). The c-Cbl protein was tyrosine phosphorylated at low level downstream from all variants, but its phosphorylation was enhanced in ®broblast expressing the Grb2 binding variant ( Figure  6 ). Since the detection of Gab1 was dicult in rat Fr3T3 cells using the available Gab1 antibodies, Gab1 phosphorylation was examined in transiently transfected 293 cells. Gab1 tyrosine phosphorylation correlated with the ability of variants to recruit Grb2 directly or indirectly through Shc (Figures 3a and 6 ). The Grb2 binding variant induced the highest levels of phosphorylation of Gab1 and c-Cbl, whereas the transforming activity of the variants binding to Shc was similar or enhanced compared to the Grb2 binding variant. This suggests that the level of tyrosine phosphorylation of Gab1 or c-Cbl does not directly correlate with the transforming capacity of the variants.
Discussion
Receptor tyrosine kinases are frequently deregulated in human cancers and this event often correlates with poor prognosis, yet the key receptor derived signals that modulate oncogenic transformation and metastatic spread are poorly understood. Previous studies addressing this question have used RTK mutants with tyrosine to phenylalanine substitutions that uncouple speci®c signaling proteins. However, with this approach one is limited to the signaling proteins that are recruited by each receptor. To overcome this limitation, we have generated a¯exible model based on the Tpr ± Met RTK oncoprotein that allows us to test the biological consequences of the recruitment of speci®c signaling proteins (Figure 1a) . We have successfully generated variant forms of the Tpr ± Met oncoprotein that recruit, in isolation, the p85 subunit of PI3'K, PLCg, or the Grb2 or Shc adaptor proteins. Substitution of amino acids 486 to 494 of the Tpr ± Met oncoprotein with sequences for signaling Figure  3c) . Moreover, the dierent Shc binding sites retained their binding selectivity for the Shc PTB domain (Figure 3b ). As predicted from the minimum binding motifs for PI3'K and PLCg (Songyang et al., 1993) , the binding sites for PI3'K and PLCg found on the PDGF receptor (pY 740 MDM and pY 1021 IIP) were favored over the pY 489 VNV found on the Tpr ± Met oncogene for direct binding. Enhanced PI3'K or PLCg were associated with the respective variants and elevated PI3'K activity was detected in cells expressing the PI3'K binding variant (Figure 2) . Together these data demonstrate that the strategy developed was permissive for the insertion of binding sites for known signaling proteins without impairing their binding capacity and speci®city.
Using these signaling speci®c binding variants, we have shown that pathways downstream from Grb2 or Shc are sucient to induce morphological transformation of ®broblasts, anchorage-independent cell growth, dispersal of epithelial cells and experimental metastasis. Studies using the PDGF receptor or Polyomavirus middle T mutants defective in their capacities to recruit PI3'K, suggested that PI3'K signaling is required for ecient cellular transformation (DeMali et al., 1997; Webster et al., 1998) . However, the Y-p85 variant, that speci®cally recruits the p85 subunit of PI3'K and strongly activates the PI3'K enzyme, behaves as a weak oncogene in a focus assay (14% eciency of Tpr ± Met). However, ®broblasts expressing the Y-p85 variant were morphologically altered and grew in soft-agar ( Figure 4 and Table 2 ). This agrees with previous studies using a constitutively activated catalytic subunit of PI3'K (p110) and an oncogene derived from the regulatory subunit of PI3'K (Jimenez et al., 1998; Klippel et al., 1998) . Considering that the formation of foci re¯ects the ability of cells to lose cell ± cell contact growth inhibition, our results suggest that in isolation, the PI3'K signal is not sucient to abrogate cell ± cell contact growth inhibition, but confers on cells the ability to grow in an anchorageindependent manner.
Many RTKs regulate the activity of the PLCg enzyme. The Y-PLCg variant that exclusively recruits and phosphorylates the PLCg enzyme was unable to eciently induce cellular transformation or promote anchorage-independent cell growth ( Figure 4 and Table  2 ). In contrast, overexpression of PLCg promoted transformation of ®broblasts, growth in an anchorageindependent manner, as well as tumor formation in nude mice (Chang et al., 1997; Smith et al., 1998) .
However, in addition to its catalytic domain, PLCg contains domains (two PH, two SH2 and one SH3 module) that mediate interaction with other proteins and phospholipids (Noh et al., 1995; Pawson, 1995) . The mechanism through which overexpression of PLCg transforms ®broblast cells is likely independent of its catalytic activity, as overexpression of the SH2-SH2-SH3 domain of PLCg induces transformation of ®broblasts comparable to that induced by PLCg (Chang et al., 1997) . These results suggest that activation of PLCg signaling pathways, in the context of a receptor oncoprotein, does not alone signi®cantly contribute to transformation of ®broblasts. The fact that overexpression of the PLCg enzyme is transforming, in contrast to the Y-PLCg variant, supports the relevance of studying signaling molecules in their normal regulatory cellular environment provided by receptor/substrate interactions.
The uncoupling of the EGFR or Tpr ± Met from Grb2, or the uncoupling of polyomavirus middle T from Shc severely impairs their oncogenic potential, implicating Grb2 or Shc dependent signals in cellular transformation (Fixman et al., 1996; Lowenstein et al., 1992; Webster et al., 1998) . However, these studies did not address whether the recruitment of Grb2 or Shc was sucient for cell transformation. We demonstrate that the direct recruitment of Grb2 or Shc to the Tpr ± Met variant is sucient to induce morphological transformation of ®broblasts and anchorage-independent growth. This supports the observation that a Neu/ ErbB-2 RTK phosphorylation-de®cient mutant oncoprotein in which only the Grb2 or Shc binding site was reintroduced is capable of inducing transformation of ®broblast cells and mammary carcinomas (Dankort et al., 1997 (Dankort et al., , 2001 ). Importantly, the Shc binding motif derived from the EGFR (Y-Shc-2 variant) had a reduced transforming activity compared to the Shc binding motif of the TrkA receptor (Y-Shc-1 variant, Table 2 and Figure 4 ) and essentially re¯ects dierences in the anity of the binding sites for Shc (Figure 3c) .
Notably, the ability of the Grb2 binding variant to transform cells was reduced when compared to that of the Y-Shc-1 variant ( Figure 4 and Table 2 ). Previous studies have correlated the phosphorylation of c-Cbl and Gab1 with cellular transformation by Tpr ± Met, and with the ability of the Tpr ± Met oncoprotein to associate with Grb2 (Bardelli et al., 1997; Fixman et al., 1997; Nguyen et al., 1997) . The c-Cbl protein was phosphorylated to a low level downstream from all variants, but signi®cantly enhanced downstream from the Grb2 binding variant (Figure 6 ). This supports a role for Grb2 in the recruitment and phosphorylation of c-Cbl by RTKs Fukazawa et al., 1996; Meisner and Czech, 1995) , but suggests that the indirect recruitment of Grb2 through Shc, as in the Y-Shc-1 and Y-Shc-2 variants, is not sucient for ecient phosphorylation of c-Cbl. Unlike c-Cbl, the tyrosine phosphorylation of Gab1 correlated with the level of Grb2 recruited directly to the Grb2 or indirectly to Grb2 or Shc signaling pathways mediate metastasis C Saucier et al the Shc binding variants (Figures 3 and 6 ). This implies that the recruitment of Grb2 directly or indirectly through Shc to RTKs is sucient to induce phosphorylation of Gab1, and is consistent with other studies (Bardelli et al., 1997; Fixman et al., 1997; Gu et al., 2000; Lock et al., 2000; . Although, the level of Gab1 phosphorylation did not directly correlate with the eciency of cellular transformation, we cannot rule out a role for Gab1 phosphorylation in cell transformation induced by the Grb2 or Shc binding variants ( Figure 6 and Table 2 ). The highest level of Gab1 phosphorylation was observed downstream from the Grb2 binding variant, whereas the Y-Shc-1 variant showed the highest transformation activity, but lower Gab1 phosphorylation, suggesting that other Shc dependent signals may be involved. The inserted sequence of the Y-Shc-1 variant represents a binding motif for the FRS2 PTB domain (Meakin et al., 1999) . Although in Fr3T3 cells we do not readily detect FRS2, it remains to be determined if the Y-Shc-1 binding variant also recruits other signaling proteins. Nevertheless, our approach allows the evaluation of the biological response of signals initiated from binding motifs derived from dierent RTKs within a common background, Tpr ± Met. The RTK derived signaling pathways involved in the acquisition of a metastatic phenotype is still unclear. In addition to cellular transformation and anchorage-independent growth, metastatic tumor cells need to gain numerous biological properties including cell motility, cell survival and secretion of extracellular matrix degrading enzymes in order to escape the primary tumor mass, invade and colonize distant organs. Dispersal of epithelial cells, a process dependent in part on cell motility, was induced by variants able to bind PI3'K, Grb2 or Shc, but not PLCg (Figure 5a ). This is consistent with a requirement for PI3'K activity, but not of PLCg for epithelial cell dispersal (Royal and Park, 1995) , and a role for Shc in dispersal of MDCK cells by the Met receptor activation (Pelicci et al., 1995) . Whereas a motile phenotype was induced by the PI3'K variant, only the Grb2 or Shc binding variant was sucient to induce metastatic spread of ®broblasts in nude mice ( Figure  5 ). This agrees with studies of Neu/ErbB-2 receptor add-back mutants where the recruitment of Grb2 induced metastatic mammary tumors in transgenic mice. However, this is inconsistent with the observation that Shc recruitment to Neu/ErbB-2 was unable to induce a metastatic response (Dankort et al., 2001) , that duplication of the Grb2 binding site in Tpr ± Met was insucient for metastatic spread of ®broblast cells (Bardelli et al., 1999) . This may re¯ect dierences in downstream signaling proteins such as Gab1 in the various cell types tested. The observation that the Grb2 and Shc binding variants showed enhanced Gab1 tyrosine phosphorylation, which in turn can recruit PI3'K, PLCg, Crk and SHP-2 to these variants, suggests that Grb2 ± Gab1 dependent signaling pathways may be required for metastasis.
The individual contribution of RTK associated proteins and their downstream signaling pathways in cellular transformation remain ill-de®ned. The signaling speci®c binding variants of Tpr ± Met represent powerful tools to identify the role of each downstream signaling pathway in common or distinct cellular events involved in cellular transformation and metastases. Moreover, the strategy that we have developed is permissive for the insertion of any binding site for known or unknown proteins and allows the evaluation of the contribution of this signal to the development of cancer.
Materials and methods
Antibodies
Antibody 144 was raised against a peptide in the carboxyterminus of the Met protein and recognizes an epitope distinct from those altered in each variant (Rodrigues et al., 1991) . Antibodies for p85, PLCg and Gab-1 were purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA), anti-phosphotyrosine, RC20H, and anti-Grb2 were from Transduction Labs (Lexington, KY, USA), anti-c-Cbl were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-Shc was kindly provided by Dr John Bergeron. GST ± Grb2 and GST ± Shc were provided by Drs Mike F Moran and Tony Pawson, respectively.
Generation of substrate specific variants of Tpr ± Met
The cloning of the Tpr ± Met, Y482F, and Y482/489F cDNAs has been previously described (Fixman et al., 1996) . For the generation of the variants, unique HpaI and NarI restriction enzyme sites were introduced into the SpeI fragment of the Tpr ± Met Y482F mutant (in pBluescript KS II) by the Chameleon TM site-directed mutagenesis system (Stratagene, La Jolla, CA, USA). Digestion with HpaI and NarI enzymes released an insert of 30 nucleotides coding for amino acids 486 to 494 of Tpr ± Met that was replaced by ligation of double stranded oligonucleotides (listed in Table  1 ). Variant cDNAs were sequenced and substituted into the Tpr ± Met backbone in pXM and pLXSN expression vectors as previously described .
Cell culture and DNA transfection
Fischer rat 3T3 (Fr3T3), MDCK, COS-1, and 293 cells were cultured at 378C in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% FBS. Transient transfections of COS-1 cells were carried out by the DEAE-dextran method and of 293 cells using Superfect (Qiagen Inc., Canada).
Cell lysate, immunoprecipitation, in vitro association assay and Western blotting Preparation of cell lysates, immunoprecipitations and Western blots and in vitro association assays were performed as described before (Fixman et al., 1996) . Proteins were visualized using enhanced chemiluminescence (ECL, Amersham) and ®lms were digitized by scanning using Adobe Photoshop. Each experiment was performed at least three times with cell lysates prepared from independent transfection.
PI3'K assays
Tpr ± Met, mutants of Tpr ± Met and variant proteins were immunoprecipitated from COS-1 cell lysates with anti-Met (Ab 144) and PI3'K assays were performed essentially as described (Fixman et al., 1995) .
Transformation assays, generation of cell lines, soft agar growth and scatter assays Transformation assays and establishment of Fr3T3 ®bro-blast stable cell lines were carried out by ecotropic retroviral infection as described (Fixman et al., 1995) . Foci and G418-resistant colonies were picked and expanded into cell lines. To evaluate the ability of each cell line to grow in an anchorage-independent manner, cells were plated in soft agar (Nobel Agar, DIFCO) as described previously (Kamikura et al., 2000) . MDCK cells (4610 5 /35-mm dish) infected with the appropriated packaged amphotropic virus as described before were selected for 2 weeks in 400 mg/ml of G418 and representative colonies photographed.
Experimental metastasis
The tail vein of CD1 nu/nu mice (Charles River, Canada) was injected with 10 5 cells/100 ml. Animals were sacri®ced at any sign of respiratory distress or weight loss, or after 70 days and examined for the presence of lung metastases.
Abbreviations RTK, receptor tyrosine kinase; SH2, Src homology domain 2; PTB, phosphotyrosine binding domain; PI3'K, phosphatidylinositol 3'-kinase; GST, glutathione S-transferase; PLCg, phospholipase Cg; IP, immunoprecipitation; FBS, fetal bovine serum.
